Browsing by Author "Micheli Y."

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing
    (Korean Academy of Asthma, Allergy and Clinical Immunology, 2020) Bousquet J.; Farrell J.; Onorato G.L.; Bedbrook A.; Czarlewski W.; Micheli Y.; Arnavielhe S.; Illario M.; Ansotegui I.J.; Anto J.M.; Bachert C.; Basagaña X.; Bédard A.; Benveniste S.; Bergmann K.C.; Bewick M.; Bindslev-Jensen C.; Bjermer L.; Blain H.; Bosnic-Anticevich S.; Bosse I.; Braido F.; Brussino L.; Camuzat T.; Canonica G.W.; Cardona V.; Carreiro Martins P.; Cecchi L.; Chavannes N.H.; Chu D.K.; Correia da Sousa J.; Costa D.J.; Costa E.; Cruz A.A.; da Silva J.; Devillier P.; de Feo G.; de Vries G.; Dray G.; Ebisawa M.; Erhola M.; Fauquert J.L.; Fokkens W.J.; Fonseca J.; Fontaine J.M.; Gemicioğlu B.; Haahtela T.; Heffler E.; Hellings P.W.; Ivancevich J.C.; Jassem E.; Jutel M.; Kaidashev I.; Kalayci O.; Klimek L.; Kowalski M.L.; Kull I.; Kuna P.; Kvedariene V.; la Grutta S.; Laune D.; Larenas-Linnemann D.; Ierodiakonou D.; Le L.T.T.; Lourenço O.; Makris M.; Menditto E.; Monti R.; Morais-Almeida M.; Münter L.; Muraro A.; Murray R.; Maurer M.; Melén E.; Mösges R.; Mullol J.; Niedoszytko M.; O'Hehir R.E.; Okamoto Y.; Papadopoulos N.G.; Passalacqua G.; Patella V.; Pereira A.M.; Pfaar O.; Pham-Thi N.; Portejoie F.; Price D.; Prokopakis E.P.; Psarros F.; Raciborski F.; Regateiro F.; Reitsma S.; Roche N.; Rolland C.; Ryan D.; Samolinski B.; Sastre J.; Scadding G.K.; Schmid-Grendelmeier P.; Schünemann H.J.; Shamji M.; Sheikh A.; Stellato C.; Suppli-Ulrik C.; Somekh D.; Sova M.; Todo Bom A.; Tomazic P.V.; Toppila-Salmi S.; Triggiani M.; Tsiligianni I.; Valero A.; Valiulis A.; Valovirta E.; van Eerd M.; Vasankari T.; Ventura M.T.; Wallace D.; Waserman S.; Yorgancioglu A.; Zidarn M.; Zuberbier T.
    The reference sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) were renewed in 2019. The DG Santé good practice Mobile Airways Sentinel networK was reviewed to meet the objectives of the EIP on AHA. It included 1) Management of care process, 2) Blueprint of digital transformation, 3) EIP on AHA, innovation to market, 4) Community for monitoring and assessment framework, 5) Political, organizational, technological and financial readiness, 6) Contributing to European co-operation and transferability, 7) Delivering evidence of impact against the triple win approach, 8) Contribution to the European Digital Transformation of Health and Care and 9) scale of demonstration and deployment of innovation. © 2020 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • No Thumbnail Available
    Item
    ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice
    (John Wiley and Sons Inc, 2021) Bousquet J.; Anto J.M.; Bachert C.; Haahtela T.; Zuberbier T.; Czarlewski W.; Bedbrook A.; Bosnic-Anticevich S.; Walter Canonica G.; Cardona V.; Costa E.; Cruz A.A.; Erhola M.; Fokkens W.J.; Fonseca J.A.; Illario M.; Ivancevich J.-C.; Jutel M.; Klimek L.; Kuna P.; Kvedariene V.; Le L.T.T.; Larenas-Linnemann D.E.; Laune D.; Lourenço O.M.; Melén E.; Mullol J.; Niedoszytko M.; Odemyr M.; Okamoto Y.; Papadopoulos N.G.; Patella V.; Pfaar O.; Pham-Thi N.; Rolland C.; Samolinski B.; Sheikh A.; Sofiev M.; Suppli Ulrik C.; Todo-Bom A.; Tomazic P.-V.; Toppila-Salmi S.; Tsiligianni I.; Valiulis A.; Valovirta E.; Ventura M.-T.; Walker S.; Williams S.; Yorgancioglu A.; Agache I.; Akdis C.A.; Almeida R.; Ansotegui I.J.; Annesi-Maesano I.; Arnavielhe S.; Basagaña X.; D. Bateman E.; Bédard A.; Bedolla-Barajas M.; Becker S.; Bennoor K.S.; Benveniste S.; Bergmann K.C.; Bewick M.; Bialek S.; E. Billo N.; Bindslev-Jensen C.; Bjermer L.; Blain H.; Bonini M.; Bonniaud P.; Bosse I.; Bouchard J.; Boulet L.-P.; Bourret R.; Boussery K.; Braido F.; Briedis V.; Briggs A.; Brightling C.E.; Brozek J.; Brusselle G.; Brussino L.; Buhl R.; Buonaiuto R.; Calderon M.A.; Camargos P.; Camuzat T.; Caraballo L.; Carriazo A.-M.; Carr W.; Cartier C.; Casale T.; Cecchi L.; Cepeda Sarabia A.M.; H. Chavannes N.; Chkhartishvili E.; Chu D.K.; Cingi C.; Correia de Sousa J.; Costa D.J.; Courbis A.-L.; Custovic A.; Cvetkosvki B.; D'Amato G.; da Silva J.; Dantas C.; Dokic D.; Dauvilliers Y.; De Feo G.; De Vries G.; Devillier P.; Di Capua S.; Dray G.; Dubakiene R.; Durham S.R.; Dykewicz M.; Ebisawa M.; Gaga M.; El-Gamal Y.; Heffler E.; Emuzyte R.; Farrell J.; Fauquert J.-L.; Fiocchi A.; Fink-Wagner A.; Fontaine J.-F.; Fuentes Perez J.M.; Gemicioğlu B.; Gamkrelidze A.; Garcia-Aymerich J.; Gevaert P.; Gomez R.M.; González Diaz S.; Gotua M.; Guldemond N.A.; Guzmán M.-A.; Hajjam J.; Huerta Villalobos Y.R.; Humbert M.; Iaccarino G.; Ierodiakonou D.; Iinuma T.; Jassem E.; Joos G.; Jung K.-S.; Kaidashev I.; Kalayci O.; Kardas P.; Keil T.; Khaitov M.; Khaltaev N.; Kleine-Tebbe J.; Kouznetsov R.; Kowalski M.L.; Kritikos V.; Kull I.; La Grutta S.; Leonardini L.; Ljungberg H.; Lieberman P.; Lipworth B.; Lodrup Carlsen K.C.; Lopes-Pereira C.; Loureiro C.C.; Louis R.; Mair A.; Mahboub B.; Makris M.; Malva J.; Manning P.; Marshall G.D.; Masjedi M.R.; Maspero J.F.; Carreiro-Martins P.; Makela M.; Mathieu-Dupas E.; Maurer M.; De Manuel Keenoy E.; Melo-Gomes E.; Meltzer E.O.; Menditto E.; Mercier J.; Micheli Y.; Miculinic N.; Mihaltan F.; Milenkovic B.; Mitsias D.I.; Moda G.; Mogica-Martinez M.-D.; Mohammad Y.; Montefort S.; Monti R.; Morais-Almeida M.; Mösges R.; Münter L.; Muraro A.; Murray R.; Naclerio R.; Napoli L.; Namazova-Baranova L.; Neffen H.; Nekam K.; Neou A.; Nordlund B.; Novellino E.; Nyembue D.; O'Hehir R.; Ohta K.; Okubo K.; Onorato G.L.; Orlando V.; Ouedraogo S.; Palamarchuk J.; Pali-Schöll I.; Panzner P.; Park H.-S.; Passalacqua G.; Pépin J.-L.; Paulino E.; Pawankar R.; Phillips J.; Picard R.; Pinnock H.; Plavec D.; Popov T.A.; Portejoie F.; Price D.; Prokopakis E.P.; Psarros F.; Pugin B.; Puggioni F.; Quinones-Delgado P.; Raciborski F.; Rajabian-Söderlund R.; Regateiro F.S.; Reitsma S.; Rivero-Yeverino D.; Roberts G.; Roche N.; Rodriguez-Zagal E.; Roller-Wirnsberger R.E.; Rosario N.; Romano A.; Rottem M.; Ryan D.; Salimäki J.; Sanchez-Borges M.M.; Sastre J.; Scadding G.K.; Scheire S.; Schmid-Grendelmeier P.; Schünemann H.J.; Sarquis Serpa F.; Shamji M.; Sisul J.-C.; Solé D.; Somekh D.; Sooronbaev T.; Sova M.; Spertini F.; Spranger O.; Stellato C.; Stelmach R.; Thibaudon M.; To T.; Toumi M.; Usmani O.; Valero A.A.; Valenta R.; Valentin-Rostan M.; Pereira M.U.; van der Kleij R.; Van Eerd M.; Vandenplas O.; Vasankari T.; Vaz Carneiro A.; Vezzani G.; Viart F.; Viegi G.; Wallace D.; Wagenmann M.; Wang D.Y.; Waserman S.; Wickman M.; Williams D.M.; Wong G.; Wroczynski P.; Yiallouros P.K.; Yusuf O.M.; Zar H.J.; Zeng S.; Zernotti M.E.; Zhang L.; Shan Zhong N.; Zidarn M.
    Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
  • No Thumbnail Available
    Item
    Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach – ARIA-EAACI Task Force Report
    (John Wiley and Sons Inc, 2023) Bousquet J.; Shamji M.H.; Anto J.M.; Schünemann H.J.; Canonica G.W.; Jutel M.; Del Giacco S.; Zuberbier T.; Pfaar O.; Fonseca J.A.; Sousa-Pinto B.; Klimek L.; Czarlewski W.; Bedbrook A.; Amaral R.; Ansotegui I.J.; Bosnic-Anticevich S.; Braido F.; Chaves Loureiro C.; Gemicioglu B.; Haahtela T.; Kulus M.; Kuna P.; Kupczyk M.; Matricardi P.; Regateiro F.S.; Samolinski B.; Sofiev M.; Toppila-Salmi S.; Valiulis A.; Ventura M.T.; Barbara C.; Bergmann K.C.; Bewick M.; Blain H.; Bonini M.; Boulet L.-P.; Bourret R.; Brusselle G.; Brussino L.; Buhl R.; Cardona V.; Casale T.; Cecchi L.; Charpin D.; Cherrez-Ojeda I.; Chu D.K.; Cingi C.; Costa E.M.; Cruz A.; Devillier P.; Dramburg S.; Fokkens W.; Gotua M.; Heffler E.; Ispayeva Z.; Ivancevich J.C.; Joos G.; Kaidashev I.; Kraxner H.; Kvedariene V.; Larenas-Linnemann D.E.; Laune D.; Lourenço O.; Louis R.; Makela M.; Makris M.; Maurer M.; Melén E.; Micheli Y.; Morais-Almeida M.; Mullol J.; Niedoszytko M.; O'Hehir R.; Okamoto Y.; Olze H.; Papadopoulos N.G.; Papi A.; Patella V.; Pétré B.; Pham-Thi N.; Puggioni F.; Quirce S.; Roche N.; Rouadi P.; Sá-Sousa A.; Sagara H.; Sastre J.; Scichilone N.; Sheikh A.; Sova M.; Suppli Ulrik C.; Taborda-Barata L.; Todo-Bom A.; Torres M.; Tsiligianni I.; Usmani O.S.; Valovirta E.; Vasankari T.; Vieira R.J.; Wallace D.; Waserman S.; Zidarn M.; Yorgancioglu A.; Zhang L.; Chivato T.; Ollert M.
    Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real-life studies and allergen challenges. Using the MASK-air app as a model, a daily electronic combined symptom-medication score for allergic diseases (CSMS) or for asthma (e-DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real-life, it secondly proposed quality-of-life digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed. © 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
  • No Thumbnail Available
    Item
    Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air® approach
    (John Wiley and Sons Inc, 2023) Bousquet J.; Anto J.M.; Sousa-Pinto B.; Czarlewski W.; Bedbrook A.; Haahtela T.; Klimek L.; Pfaar O.; Kuna P.; Kupczyk M.; Regateiro F.S.; Samolinski B.; Valiulis A.; Yorgancioglu A.; Arnavielhe S.; Basagaña X.; Bergmann K.C.; Bosnic-Anticevich S.; Brussino L.; Canonica G.W.; Cardona V.; Cecchi L.; Chaves-Loureiro C.; Costa E.; Cruz A.A.; Gemicioglu B.; Fokkens W.J.; Ivancevich J.C.; Kraxner H.; Kvedariene V.; Larenas-Linnemann D.E.; Laune D.; Louis R.; Makris M.; Maurer M.; Melén E.; Micheli Y.; Morais-Almeida M.; Mullol J.; Niedoszytko M.; Okamoto Y.; Papadopoulos N.G.; Patella V.; Pham-Thi N.; Rouadi P.W.; Sastre J.; Scichilone N.; Sheikh A.; Sofiev M.; Taborda-Barata L.; Toppila-Salmi S.; Tsiligianni I.; Valovirta E.; Ventura M.T.; Vieira R.J.; Zidarn M.; Amaral R.; Ansotegui I.J.; Bédard A.; Benveniste S.; Bewick M.; Bindslev-Jensen C.; Blain H.; Bonini M.; Bourret R.; Braido F.; Carreiro-Martins P.; Charpin D.; Cherrez-Ojeda I.; Chivato T.; Chu D.K.; Cingi C.; Del Giacco S.; de Blay F.; Devillier P.; De Vries G.; Doulaptsi M.; Doyen V.; Dray G.; Fontaine J.-F.; Gomez R.M.; Hagemann J.; Heffler E.; Hofmann M.; Jassem E.; Jutel M.; Keil T.; Kritikos V.; Kull I.; Kulus M.; Lourenço O.; Mathieu-Dupas E.; Menditto E.; Mösges R.; Murray R.; Nadif R.; Neffen H.; Nicola S.; O’Hehir R.; Olze H.; Palamarchuk Y.; Pépin J.-L.; Pétré B.; Picard R.; Pitsios C.; Puggioni F.; Quirce S.; Raciborski F.; Reitsma S.; Roche N.; Rodriguez-Gonzalez M.; Romantowski J.; Sá-Sousa A.; Serpa F.S.; Savouré M.; Shamji M.H.; Sova M.; Sperl A.; Stellato C.; Todo-Bom A.; Tomazic P.V.; Vandenplas O.; Van Eerd M.; Vasankari T.; Viart F.; Waserman S.; Fonseca J.A.; Zuberbier T.
    MASK-air®, a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air® results should lead to change management in rhinitis and asthma. © 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.